Formulation Batch Manufacturing for Oral Direct Compression Tablets

Posted on by Pharmacist
Formulation Batch Manufacturing for Oral Direct Compression Tablets

Objective of Formulation Batch Manufacturing

Taj Pharma's Third Party Manufacturing
Taj Pharma’s Third Party Manufacturing

The manufacturing of oral direct compression tablets at a Contract Manufacturing Organization (CMO) plays a critical role in supporting stability studies, bioequivalence (BE) studies, clinical trials, and commercial scale-up. The objective is to ensure that all processes comply with current Good Manufacturing Practices (cGMP), ICH guidelines, and global regulatory requirements. By executing precise manufacturing processes, organizations safeguard product quality, patient safety, and regulatory compliance throughout the product lifecycle.

Roles and Responsibilities in Tablet Manufacturing

Customer Responsibilities

  • Provide the approved manufacturing formula and batch manufacturing record (BMR).
  • Share API and excipient specifications, including certificates of analysis and quality standards.
  • Deliver testing methods, product specifications, and validated stability protocols.
  • Ensure that all documentation aligns with regulatory and clinical trial requirements.

CMO Responsibilities

  • Obtain necessary import licenses for APIs and regulatory permissions for manufacturing clinical or pivotal study batches.
  • Execute batch manufacturing as per the approved BMR, following GMP guidelines.
  • Maintain environmental controls (temperature, humidity, particulate levels) in classified manufacturing areas.
  • Perform primary and secondary packaging according to approved packaging instructions.
  • Conduct stability studies under ICH-recommended conditions.
  • Supply qualified clinical trial material to the study site within stipulated timelines.

Formulation Batch Details

  • Batch Size
    • Pilot Batch (Stability): 5,000 tablets
    • Clinical Batch: 50,000 tablets
    • Commercial Validation Batch: 3 × 100,000 tablets
  • Strength(s): Single-strength or multiple-strength formulations depending on the clinical and regulatory requirement.
  • Intended Use: Stability, BE/PK studies, and commercial validation.

Formulation Process for Direct Compression Tablets

Process Flow

  1. Raw Material Dispensing – Each raw material, including API and excipients, is weighed using calibrated balances in a classified dispensing area.
  2. Sifting/Sieving – Materials pass through sieves of appropriate mesh size to remove lumps and ensure uniform particle size distribution.
  3. Blending of API and Excipients – API is mixed with filler excipients (such as MCC, lactose, or mannitol) to achieve content uniformity.
  4. Lubricant Addition – Lubricants like magnesium stearate or colloidal silica are added to improve powder flow and prevent sticking during compression.
  5. Compression into Tablets – The blend is compressed using a rotary tablet press with tooling specifications (e.g., 6.5 mm round or 13 × 7 mm oval tooling).
  6. Primary Packaging – Tablets are packed in Alu-Alu blister packs to protect against moisture and light.

Manufacturing Conditions

  • Temperature: ≤ 30°C
  • Relative Humidity (RH): ≤ 35% (can be extended up to 40% if validated)

Equipment Requirements

  • Calibrated weighing balances
  • Blender (double-cone, V-blender, or bin blender)
  • Compression machine (rotary press)
  • Packing machine (for Alu-Alu blisters and cartons)
  • Roller compactor (if vendor-supplied raw materials do not meet compressibility specifications)

Analytical Testing and Sample Management

All manufactured batches undergo a rigorous quality control program to ensure compliance with regulatory standards.

Tests to be performed include:

  • Appearance (visual inspection of tablets)
  • Assay by HPLC (active ingredient quantification)
  • Content Uniformity (to ensure even drug distribution across tablets)
  • Dissolution Studies (to confirm drug release profile)
  • Related Substances/Impurities (stability-indicating tests)
  • Moisture Content (Karl Fischer or LOD method)
  • Microbial Limits Testing (when required by product category)

Sample Retention:

  • Stability samples per ICH Q1A guidelines
  • Reference samples for regulatory submissions
  • Retention samples as per GMP compliance

Packaging Requirements

Primary Packaging

  • Alu-Alu blister packs in units of 10 tablets.

Secondary Packaging

  • Printed cartons with patient information leaflet.

Clinical Labeling

  • Must comply with IRB/ethics committee and regulatory requirements, including:
    • Batch number
    • Expiry date
    • Storage conditions
    • Patient dosing instructions

Commercial Packaging

  • Market-specific artwork and language requirements.
  • Compliance with local drug regulatory authority guidelines.

Stability Study Plan

Stability studies are conducted to assess shelf life, packaging compatibility, and degradation profile.

Storage Conditions

  • Long-term: 25°C ± 2°C / 60% ± 5% RH
  • Accelerated: 40°C ± 2°C / 75% ± 5% RH
  • Intermediate: 30°C ± 2°C / 65% ± 5% RH

Time Points

  • 0, 1, 3, 6, 9, 12, 18, and 24 months

Parameters to Monitor

  • Physical appearance
  • Assay and related substances
  • Dissolution profile
  • Water content
  • Microbiological quality (if applicable)

Transport and Storage Requirements

To maintain drug quality and stability during transportation, strict protocols are followed:

  • Mode of Transport: Qualified couriers using temperature-controlled vehicles.
  • Temperature Ranges:
    • APIs: 2–8°C
    • Finished dosage forms (FDFs): 15–25°C
  • Data Logging: Temperature monitoring using validated data loggers.
  • Packaging: Insulated shippers with gel packs or phase change materials to ensure validated thermal protection.

Documentation Deliverables

A robust documentation package is mandatory to support regulatory compliance and audit readiness.

  • Master Batch Record (MBR) & Batch Manufacturing Record (BMR)
  • Certificates of Analysis (CoA) for raw materials and finished product
  • Deviation and CAPA reports (if applicable)
  • Stability study protocols and interim reports
  • Transport validation and shipment reports

The formulation and manufacturing of direct compression oral tablets involve strict compliance with cGMP, ICH, and regulatory requirements. From raw material dispensing to packaging, stability studies, and clinical supply, every stage must be meticulously controlled. By implementing robust process controls, validated equipment, and stringent quality systems, manufacturers ensure patient safety, regulatory approval, and commercial success.